thiotepa has been researched along with Seizures in 2 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 7.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 3.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| "Serious neurological adverse events (NAE) have occurred during treatment with high-dose thiotepa regimens of children with high-risk solid tumours." | 1.48 | High-dose thiotepa-related neurotoxicity and the role of tramadol in children. ( Demirdjian, S; Dufour, C; Laplanche, A; Lemare, F; Maritaz, C; Valteau-Couanet, D, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maritaz, C | 1 |
| Lemare, F | 1 |
| Laplanche, A | 1 |
| Demirdjian, S | 1 |
| Valteau-Couanet, D | 1 |
| Dufour, C | 1 |
| Cacchione, A | 1 |
| LeMaitre, A | 1 |
| Couanet, DV | 1 |
| Benhamou, E | 1 |
| Amoroso, L | 1 |
| Simonnard, N | 1 |
| Hartmann, O | 1 |
2 other studies available for thiotepa and Seizures
| Article | Year |
|---|---|
High-dose thiotepa-related neurotoxicity and the role of tramadol in children.
Topics: Adolescent; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2018 |
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; | 2008 |